Resource Logo
CDC HIV/AIDS/Viral Hepatitis/STD/TB Prevention News Update

UNITED STATES: Bristol-Myers, Gilead Work on New Combo HIV Pill




 

Associated Press (10.26.11) - Thursday, October 27, 2011

Bristol-Myers Squibb Co. and Gilead Sciences Inc. announced Wednesday a deal to develop and sell a once-a-day HIV pill that combines a popular protease inhibitor (PI) with a boosting agent.

Under the plan, Bristol-Myers will formulate, manufacture, and sell the combination treatment. The pill includes Bristol- Myers' PI Reyataz and Gilead's cobicistat, which works to raise HIV drug levels in the blood by blocking an enzyme that breaks down drugs. Gilead is currently conducting mid- and late-stage human trials of the combination pill in newly diagnosed patients.

The two companies already work together on the three-drug pill Atripla, the first approved once-a-day HIV drug; it is now prescribed to more than half of new HIV patients. Atripla includes Sustiva, made by Bristol-Myers, and Gilead's Viread and Emtriva.

Combination pills have become the foundation of HIV treatment, as they make regimen adherence much less difficult.



 


Copyright © 2011 -CDC Prevention News Update, Publisher. All rights reserved to Information, Inc., Bethesda, MD. The CDC National Center for HIV, STD and TB Prevention provides the following information as a public service only. Providing synopses of key scientific articles and lay media reports on HIV/AIDS, other sexually transmitted diseases and tuberculosis does not constitute CDC endorsement. This daily update also includes information from CDC and other government agencies, such as background on Morbidity and Mortality Weekly Report (MMWR) articles, fact sheets, press releases and announcements. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC HIV/STD/TB Prevention News Update should be cited as the source of the information. Contact the sources of the articles abstracted below for full texts of the articles.



Information in this article was accurate in October 27, 2011. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.